ACTRN12618001429246已完成4 期
An open label study to assess the efficacy, safety and tolerability of pyronaridine-artesunate (Pyramax) in the treatment of malaria infection caused by single or mixed species of Plasmodium falciparum, P. vivax, or P. malariae in Vietnamese patients living in Dak Nong Province, central west-highlands of Vietnam
S Naval Medical Research Center-Asia and US Naval Medical Research Unit - Two0 个研究点目标入组 110 人开始时间: 2018年8月27日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 8 Years 至 o limit（—）
- 性别
- All
入选标准
- •Adults and children with a body weight greater than or equal to 20 kg
- •Symptomatic of malaria infection (i.e. history of fever within 24 hours and/or presence of fever greater than 37.5°C for axillary temperature or greater than 38.0°C for tympanic temperature.
- •Microscopic confirmation of asexual (i.e. blood) stages of mono-infections of P. falciparum, P. vivax and P. malariae or mixed infections of the Plasmodium species.
- •Parasitemia between 250/µL and less than 100 000/µL of blood.
- •Glucose-6-Phosphate Dehydrogenase (G6PD) normal participants with mono-infection of P. vivax or mixed infections of P. vivax will be treated with primaquine to kill liver hypnozoites.
- •Ability to take oral medication. Written informed consent given to participate in the trial by the patient or in case of children up to 17 years old (assent for children aged 10 to 17 years old) with adult or guardian permission.
排除标准
- •Pregnancy or lactation (urine test for ß HCG to be performed on any woman of child bearing age 10 to 55 years old).
- •Hematocrit less than 20%.
- •Parasitemia less than 250/µL or greater than 100 000/µL of blood.
- •Signs or symptoms indicative of severe/cerebral malaria (WHO, 2014).
- •Liver function test (AST/ALT levels) more than 2.5 times the upper limit of normal (ULN) range.
- •Total bilirubin greater than 2 ULN.
- •Use of an antimalarial drug in the preceding 4 weeks.
- •History of splenectomy, heavy alcohol use or injecting drugs of abuse.
- •Any other condition, which in the judgment of the study physician would make participation in the study unsafe for the potential study participant.
研究者
相似试验
招募中
3 期
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemia2023-508455-38-00AstraZeneca AB58
进行中（未招募）
1 期
A study to investigate increasing doses of Sodium Zirconium Cyclosilicate (SZC) in children under 18 years old who have high blood potassium levels (Hyperkalaemia ). This research is to find out if SZC will work and be safe for the treatment of hyperkalaemia in children under 18 years of age.EUCTR2018-001331-48-PLAstraZeneca AB140
招募中
1 期
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemiaHyperkalaemiaMedDRA version: 21.1Level: LLTClassification code: 10020647Term: Hyperkalemia Class: 10027433CTIS2023-508455-38-00AstraZeneca AB140
招募中
3 期
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemiaHyperkalaemiaJPRN-jRCT2031220173Ageishi Yuji3
尚未招募
4 期
To evaluate the effect of PentaSure fibersupplementation in the management of Functional Constipation among ChildreCTRI/2023/10/058430Hexagon Nutrition Limited